Picard Medical: NYSE American Accepts Compliance Plan, Listing Preserved

What Happened Picard Medical, Inc. filed an 8-K on July 27, 2026 reporting that the NYSE American accepted the company’s Compliance Plan on July 22, 2026. The acceptance addresses noncompliance with NYSE American continued listing standards (Sections 1003(a)(i) and (ii)) that were previously disclosed in 8-Ks on May 11 and May 21, 2026. The company had reported stockholders’ equity of $3.8 million as of December 31, 2025, a stockholders’ deficit of $(1.4) million as of March 31, 2026, and losses in three of its four most recent fiscal years ended December 31, 2025. Picard also issued a press release on July 27, 2026 announcing the acceptance.

Key Details

• NYSE American accepted Picard’s Compliance Plan on July 22, 2026, allowing the company to remain listed.
• Reported balances: $3.8 million stockholders’ equity (12/31/2025) and $(1.4) million stockholders’ deficit (3/31/2026).
• Company has up to 18 months from the original notice of noncompliance to regain compliance and will be subject to quarterly review by NYSE American.
• Press release announcing the acceptance was issued July 27, 2026 (Exhibit 99.1 to the 8-K).

Why It Matters This filing means Picard’s shares remain listed on the NYSE American for now, which preserves market access and liquidity for shareholders. However, the continued listing depends on meeting the milestones in the Compliance Plan within the allowed timeframe and passing ongoing quarterly reviews; failure to do so could lead to delisting. Investors should monitor the company’s progress against the Compliance Plan and its upcoming financial results for signs of sustained improvement.